AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29465583 — intervention group
Group type: COMPARATOR
Intervention: Living Low-Training Low (LLTL)
Number of subjects: 35
Study 26828788 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus bevacizumab
Number of subjects: 100
Study 26828788 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 100
Study 24141905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized zirconium total knee prosthesis
Number of subjects: 12
Study 24141905 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium total knee prosthesis
Number of subjects: 12
Study 22334314 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Kissing Balloon Dilatation (FKBD)
Number of subjects: 75
Study 22334314 — intervention group
Group type: COMPARATOR
Intervention: No FKBD
Number of subjects: 75
Study 21199410 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 added to systemic steroid treatment for 2 weeks.
Number of subjects: 120
Study 21199410 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid treatment for 2 weeks (control group).
Number of subjects: 120
Study 17469983 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 17469983 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16014882 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Number of subjects: 731
Study 16014882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 12201869 — intervention group
Group type: EXPERIMENTAL
Intervention: INF-alpha 10 MU/m2 and LAM 4 mg/kg (max 100 mg) for 6 months, then LAM alone for 6 months
Number of subjects: 32
Study 12201869 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM alone for the first 2 months, then INF-alpha added for 6 months, then LAM alone for 4 months
Number of subjects: 32
Study 12201869 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 32
Study 10885834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) ET-1 concentration in patients with HIV encephalopathy (grade 1-3)
Number of subjects: 48
Study 10885834 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) ET-1 concentration in patients without encephalopathy (grade 0-0.5)
Number of subjects: 48
Study 10885834 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ET-1 CSF concentrations and degree of HIV encephalopathy
Number of subjects: 48
Study 10885834 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ET-1 levels in CSF and IgG serum to CSF ratio
Number of subjects: 48
Study 10885834 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HIV encephalopathy and CSF total protein, IgG, albumin, or serum to CSF ratio of IgG or albumin
Number of subjects: 48
Study 8943865 — intervention group
Group type: EXPERIMENTAL
Intervention: CD2 antigen positive leukemic cells (> 75% positivity)
Number of subjects: 651
Study 8943865 — intervention group
Group type: EXPERIMENTAL
Intervention: CD2‐negative patients
Number of subjects: 651
Study 8943865 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk T‐lineage ALL (CD2‐negative)
Number of subjects: 651
Study 8943865 — intervention group
Group type: COMPARATOR
Intervention: High-risk T‐lineage ALL (CD2 positive)
Number of subjects: 651
Study 2248073 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg daily for the first 5 days, then up to 600 mg)
Number of subjects: 75
Study 2248073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (starting at 33 mg, increased to 100 mg/day in the first 5 days, then could be further increased)
Number of subjects: 75
Study 2248073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 7227770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 50
Study 7227770 — intervention group
Group type: COMPARATOR
Intervention: Mylanta II
Number of subjects: 50
Study 7227770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (in smokers)
Number of subjects: 50
Study 7227770 — intervention group
Group type: COMPARATOR
Intervention: Mylanta II (in smokers)
Number of subjects: 50
Study 7227770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (in nonsmokers)
Number of subjects: 50
Study 7227770 — intervention group
Group type: COMPARATOR
Intervention: Mylanta II (in nonsmokers)
Number of subjects: 50
Study 7227770 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (effect on healing)
Number of subjects: 50
Study 30280328 — intervention group
Group type: EXPERIMENTAL
Intervention: New complete denture and simple dietary advice
Number of subjects: 0
Study 30280328 — intervention group
Group type: COMPARATOR
Intervention: New complete denture and denture care advice
Number of subjects: 0
Study 27744075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer acetate (RAC)
Number of subjects: 58
Study 27744075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES; 130 kDa/0.4)
Number of subjects: 58
Study 27744075 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 58
Study 27744075 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 58
Study 26411328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide (10 mg tid) with insulin glargine
Number of subjects: 156
Study 26411328 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.2 mg tid) with insulin glargine
Number of subjects: 156
Study 24684973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 489
Study 23181446 — intervention group
Group type: EXPERIMENTAL
Intervention: Global secondary low back pain prevention program (two-hour information session + five weekly 90-min exercise sessions)
Number of subjects: 100
Study 23181446 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 100
Study 19819448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2mg/day
Number of subjects: 64
Study 19819448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 4mg/day
Number of subjects: 64
Study 19819448 — intervention group
Group type: COMPARATOR
Intervention: Dienogest 1mg/day
Number of subjects: 64
Study 17352961 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic bacteria (1 x 10^10 colony-forming units/d)
Number of subjects: 50
Study 17352961 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose (placebo)
Number of subjects: 50
Study 15860519 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stent implantation
Number of subjects: 142
Study 15860519 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 142
Study 11994812 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program focusing on strengthening hip and knee extensors
Number of subjects: 23
Study 11994812 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification techniques to avoid shoulder overuse
Number of subjects: 23
Study 11994812 — intervention group
Group type: COMPARATOR
Intervention: Combination of exercise and lifestyle modification
Number of subjects: 23
Study 9816650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 micrograms PGE1 over a period of 2 hours
Number of subjects: 20
Study 9816650 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 20
Study 7694917 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality graded exposure treatment (N = 10)
Number of subjects: 20
Study 7694917 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list comparison group (N = 7)
Number of subjects: 20
Study 2695647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple Stimulation Contraction Stress Tests (BSTs)
Number of subjects: 103
Study 2695647 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin Challenge Tests (OCTs)
Number of subjects: 103
Study 7414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomized subjects
Number of subjects: 13
Study 7414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertransfused subjects
Number of subjects: 13
Study 7414298 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 13
Study 7414298 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 13
Study 7414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Controls and hypertransfused subjects only
Number of subjects: 13
Study 31917372 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER mobile phone app for monitoring well-being and early warning signs (EWSs) of relapse, blended with ongoing peer support.
Number of subjects: 120
Study 31917372 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 120
Study 31870415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program (CHAP) for 1 year
Number of subjects: 28
Study 31870415 — intervention group
Group type: COMPARATOR
Intervention: Matched buildings not receiving the CHAP program
Number of subjects: 28
Study 28107559 — intervention group
Group type: EXPERIMENTAL
Intervention: AVX001 (cPLA2α inhibitor) at 5% dose level
Number of subjects: 94
Study 28107559 — intervention group
Group type: EXPERIMENTAL
Intervention: AVX001 (combined doses of 3% and 5%)
Number of subjects: 94
Study 28107559 — intervention group
Group type: EXPERIMENTAL
Intervention: AVX001 (any dose)
Number of subjects: 94
Study 28107559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 25842385 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based worksite weight loss intervention
Number of subjects: 1030
Study 25842385 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 1030
Study 23953069 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH-based algorithm
Number of subjects: 348
Study 23953069 — intervention group
Group type: COMPARATOR
Intervention: AFC-based algorithm
Number of subjects: 348
Study 20961479 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol and Olanzapine
Number of subjects: 420
Study 20961479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 19342174 — intervention group
Group type: EXPERIMENTAL
Intervention: tricyclic antidepressant medication
Number of subjects: 169
Study 19342174 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study 19342174 — intervention group
Group type: EXPERIMENTAL
Intervention: (cognitive-behavioral) stress-management therapy plus placebo
Number of subjects: 169
Study 19342174 — intervention group
Group type: EXPERIMENTAL
Intervention: stress-management therapy plus antidepressant medication
Number of subjects: 169
Study 19708873 — intervention group
Group type: EXPERIMENTAL
Intervention: Short incubation with ALA plus IPL (30 minutes, n=9)
Number of subjects: 20
Study 19708873 — intervention group
Group type: EXPERIMENTAL
Intervention: Long incubation with ALA plus IPL (3 hours, n=11)
Number of subjects: 20
Study 19708873 — intervention group
Group type: COMPARATOR
Intervention: IPL alone
Number of subjects: 20
Study 15869575 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity warfarin (INR range 3.0-4.5)
Number of subjects: 109
Study 15869575 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (warfarin, INR range 2.0-3.0 or aspirin 100 mg/day)
Number of subjects: 109
Study 15869575 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity warfarin
Number of subjects: 109
Study 15869575 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 109
Study 12473001 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 115
Study 12473001 — intervention group
Group type: COMPARATOR
Intervention: Control (low-intensity home exercise program)
Number of subjects: 115
Study 9585282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Number of subjects: 98
Study 9585282 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Number of subjects: 98
Study 7620002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime monotherapy
Number of subjects: 580
Study 7620002 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone/tobramycin
Number of subjects: 580
Study 2696203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (oral)
Number of subjects: 107
Study 2696203 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 1.6 mg (inhalation)
Number of subjects: 107
Study 324398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 90
Study 324398 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ
Number of subjects: 90
Study 324398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 324398 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 90
Study 11601118 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg daily
Number of subjects: 590
Study 11601118 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg daily
Number of subjects: 590
Study 11601118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study 11601118 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 590
Study 11601118 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 590
Study 31077411 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols with primary outcomes defined
Number of subjects: 49
Study 31077411 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols with primary outcomes omitted
Number of subjects: 49
Study 31077411 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols with new primary outcomes introduced
Number of subjects: 49
Study 31077411 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols with discrepancies in primary outcome time frame
Number of subjects: 49
Study 31077411 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols with new secondary outcomes introduced
Number of subjects: 49
Study 31077411 — intervention group
Group type: COMPARATOR
Intervention: Industry funding
Number of subjects: 49
Study 31077411 — intervention group
Group type: COMPARATOR
Intervention: Timing of registration
Number of subjects: 49
Study 29713153 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal cannula (HFNC)
Number of subjects: 200
Study 29713153 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 27221939 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for gall bladder cancer in high risk populations
Number of subjects: 0
Study 27221939 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 23982816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 107
Study 23982816 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 107
Study 22410609 — intervention group
Group type: EXPERIMENTAL
Intervention: Elder health promotion program (health education and exercise) led by a professional leader for 4 weeks, followed by elder health leader and research assistant for 8 weeks (total 12 weeks)
Number of subjects: 49
Study 22410609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 49
Study 20197789 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry group (diet 1, N=31, 28 completed)
Number of subjects: 61
Study 20197789 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet 2, N=30, 22 completed)
Number of subjects: 61
Study 17694944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual acid etched and further conditioned with nanometer‐scale crystals of calcium phosphate (n = 9)
Number of subjects: 18
Study 17694944 — intervention group
Group type: COMPARATOR
Intervention: Dual acid etched (n = 9)
Number of subjects: 18
Study 15655140 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% salicylic acid gel plus 0.1% tacrolimus ointment
Number of subjects: 30
Study 15655140 — intervention group
Group type: COMPARATOR
Intervention: 6% salicylic acid gel plus vehicle
Number of subjects: 30
Study 11860410 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment in H. pylori-positive patients (36 patients)
Number of subjects: 66
Study 11860410 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative/cured patients (43 patients)
Number of subjects: 66
Study 10439762 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramid combined with pleural bupivacaine
Number of subjects: 37
Study 10439762 — intervention group
Group type: COMPARATOR
Intervention: Piritramid alone
Number of subjects: 37
Study 7843703 — intervention group
Group type: EXPERIMENTAL
Intervention: Total paracentesis associated with plasma volume expansion
Number of subjects: 80
Study 7843703 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 80
Study 2297284 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol diet
Number of subjects: 10
Study 2297284 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/d cholesterol diet
Number of subjects: 10
Study 856917 — intervention group
Group type: EXPERIMENTAL
Intervention: H3ChN2Ch virus vaccine
Number of subjects: 0
Study 856917 — intervention group
Group type: EXPERIMENTAL
Intervention: Heq1N2Ch virus vaccine
Number of subjects: 0
Study 856917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31829227 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) testing (i-STAT and complete blood count (CBC), electrocardiograms (ECGs), and x-rays (LODOX®))
Number of subjects: 897
Study 31829227 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) testing (LODOX®-containing permutations)
Number of subjects: 897
Study 31829227 — intervention group
Group type: COMPARATOR
Intervention: Standard ED pathway with traditional diagnostic tests
Number of subjects: 897
Study 29410545 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental transfusion (DCC or CM)
Number of subjects: 461
Study 29410545 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 461
Study 26802800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (6 weeks)
Number of subjects: 136
Study 26802800 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 136
Study 24512061 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic future thinking (EFT) with positive valence
Number of subjects: 87
Study 24512061 — intervention group
Group type: COMPARATOR
Intervention: Episodic future thinking (EFT) with neutral valence
Number of subjects: 87
Study 24512061 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive episodic thinking
Number of subjects: 87
Study 22876748 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg for three weeks
Number of subjects: 15
Study 22876748 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three weeks
Number of subjects: 15
Study 20712805 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.1 mg.kg⁻¹
Number of subjects: 38
Study 20712805 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone 0.05 mg.kg⁻¹
Number of subjects: 38
Study 20712805 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone 0.1 mg.kg⁻¹
Number of subjects: 38
Study 20712805 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone 0.2 mg.kg⁻¹
Number of subjects: 38
Study 20712805 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 38
Study 17534634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone ointment
Number of subjects: 10
Study 17534634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15333614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast immobilization
Number of subjects: 0
Study 15333614 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation after immobilization
Number of subjects: 0
Study 15333614 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro force mechanics on skinned human muscle fibers
Number of subjects: 0
Study 11192337 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted behavioral treatment
Number of subjects: 197
Study 11192337 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment with oxybutynin chloride
Number of subjects: 197
Study 11192337 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control condition
Number of subjects: 197
Study 9625122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 9625122 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 5 mg/day
Number of subjects: 79
Study 9625122 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 10 mg/day
Number of subjects: 79
Study 9625122 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg q.i.d.
Number of subjects: 79
Study 7837401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 0
Study 7837401 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 0
Study 7837401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sevoflurane and isoflurane anesthesia
Number of subjects: 0
Study 3166825 — intervention group
Group type: EXPERIMENTAL
Intervention: All program components (lifestyle assessment, physician prescription of lifestyle change, educational materials)
Number of subjects: 0
Study 3166825 — intervention group
Group type: EXPERIMENTAL
Intervention: Parts of the program
Number of subjects: 0
Study 3166825 — intervention group
Group type: COMPARATOR
Intervention: No program components
Number of subjects: 0
Study 31764824 — intervention group
Group type: COMPARATOR
Intervention: MRCP alone
Number of subjects: 38
Study 31764824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MRI including DWI
Number of subjects: 38
Study 28527228 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for bilateral quadriceps muscles for 2 weeks
Number of subjects: 20
Study 28527228 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 26392433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous bone marrow mononuclear cells (BMNC)
Number of subjects: 160